Shoppers are switching traditional toothbrushes for this Philips electric model while it's half price
Toothbrushing isn't supposed to be sexy. But tell that to the thousands of Aussies snapping up the Philips Sonicare DiamondClean 9000 Black + Pink Rechargeable Electric Toothbrush Bundle like it's a designer handbag.
Part of Amazon Australia's mid-year sale, the sleek, high-tech toothbrush set is down from $619 to just $319 for a limited time. That's nearly half price for two premium brushes, which makes it perfect for couples, or for single people who just really, really love dental hygiene.
With over 50,000 recent orders and a glowing 92 per cent positive rating from 10,000 customers, it's clear this isn't your average electric toothbrush.
In fact, one reviewer summed it up best: 'Brushing feels like a high-tech spa treatment.'
So, what makes it worth the hype and the investment? It literally tells you if you're brushing too hard.
Ever been told off by a toothbrush? This one pulses if you're brushing too hard, gently reminding you to ease up.
According to Philips, seven out of ten users said this feature helped them become better brushers. It's like having a mini dentist in your bathroom. Minus the guilt trip.
It knows what your teeth need
Thanks to BrushSync technology, the brush recognises the head you're using and automatically adjusts the mode and intensity. For example, pop on the W3 Premium White brush head and the DiamondClean 9000 will switch to White+ mode to help lift surface stains.
You don't even need to guess when it's time for a replacement, the handle gives you a gentle beep and reminder based on how often you brush and how hard you've been going at it.
It has four modes, three intensities and one major flex.
The DiamondClean 9000 isn't just about cleaning your teeth. It's about doing it your way.
And then fine-tune with three intensity settings depending on your sensitivity or how aggressive your coffee habit's been lately.
One customer even called it ' a lifestyle decision '.
Honestly, they're not wrong. With a 14-day battery life, a premium glass charging cup, and a sleek black and pink design that looks more like a luxury gadget than a dental tool, the DiamondClean 9000 is brushing reimagined.
'I can definitely feel the difference,' wrote another happy shopper.
'My gum health is stable, and my breath is no longer a problem.'
It's the kind of toothbrush that makes you want to book a holiday just so you can pack it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
a day ago
- News.com.au
More people taking sick leave as Australia braces for ‘nasty' flu season and new Covid strain
The number of Aussies taking sick leave has sharply risen as a new Covid subvariant takes hold and the country braces for a 'nasty' winter flu season. can reveal telehealth sick note provider Sicky reported a 108 per cent year-on-year increase in flu-related sick leave requests in March and April, and a 24 per cent rise in Covid-related sick leave requests. Pharmacist Avinash Vazirani, who co-founded Sicky, told us the company had seen an 11 per cent increase in sick certificate requests tied to travel-related flu and Covid cases compared to the same time last year. 'Travel is back in full swing, which is great news for the soul, but it also comes with a few risks,' he said. 'When you board a plane, you're stepping into a confined environment for hours with recirculated air and shared surfaces. That's the perfect storm for transmissible illnesses like Covid-19 and the flu.' Mr Vazirani has urged people who have tested positive to Covid before a flight to reconsider their travel plans. His advice for preventive measures on board? 'Wear a well-fitted mask during the flight, especially when you're not eating or drinking, sanitise your hands often, especially after touching common surfaces or using the loo, and avoid touching your face,' he said. Mr Vazirani stressed that being cautious isn't overkill — 'it's just smart travel'. 'Aussies have a reputation for being proactive about their health, and we're lucky to have access to one of the world's best healthcare systems, but that safety net doesn't travel with your suitcase,' he said. 'Overseas, getting sick can mean language barriers, different medication standards, or even no access to medical help at all depending on where you are. Plus, healthcare costs in some countries can be eye-watering.' While Sicky doesn't know if the increase in Covid-related sick note requests is due to the new NB. 1.8.1 Covid variant, because they don't track the exact strain people have, Mr Vazirani said 'pandemic fatigue is real' and people appear to have eased off on habits like hand sanitising and mask-wearing. The NB. 1.8.1 Covid variant has been designated a Variant Under Monitoring (VUM) by the World Health Organisation as the UN agency says 'continued monitoring is essential'. Since first being recognised in January, it has become the dominant strain in Hong Kong and China, and has been increasing in other countries, including across Australia. It was revealed last week wastewater testing estimates 40 per cent of Covid cases in Victoria, and 50 per cent of cases in Western Australia, are a result of NB. 1.8.1. Health authorities are now speaking out with a push for booster jabs. Health Minister Mark Butler has urged older people, in particular, to get vaccinated and younger people to consider getting a booster too. 'This is another member of the big, sprawling Omicron family,' Mr Butler said on Friday. 'This is pretty consistent with patterns we've seen now for a few years, where a new subvariant of Omicron emerges and starts to spread across the world.' Dr Paul Griffin, director of infectious diseases at Mater Health in Brisbane, said NB. 1.8.1 was 'driving up infections and hospitalisations, particularly in Asia and Western Australia'. 'The best way to protect yourself and your family is to get the newest booster which provides very good coverage, is safe, and will reduce the severity of your symptoms if you contract Covid-19,' he said. As for the flu, in the first three months of the year there were 48,586 lab confirmed cases of influenza, according to the National Notifiable Disease Surveillance Dashboard. That is compared to 30,492 lab confirmed cases during the same period in 2024. Griffith University virologist Associate Professor Lara Herrero has described this flu season as 'nasty,' urging people to also get their annual flu jab. In Victoria, Western Health Chief Operating Officer John Ferraro confirmed changes have been made at his hospitals in response to increase in transmission of influenza, Covid, RSV and measles. He told 3AW that staff were required to wear surgical masks in all patient facing areas, and visitor restrictions had been introduced that rules patients are allowed two visitors each for up to two hours per day. It came after a Victorian woman called the radio show and told them she could not visit her dad in an unnamed hospital. 'On Sunday we were told that there's Covid in the hospital and that we needed to mask up if we wanted to come visit. Today we were told we're not allowed to visit,' the caller said on Tuesday.
ABC News
3 days ago
- ABC News
Philips Electronics faces legal action for selling allegedly 'unsafe' breathing devices
The Therapeutic Goods Administration has started legal proceedings against tech giant Philips Electronics over allegations the company unlawfully sold assisted breathing devices in Australia. The devices were used by many people with sleep apnoea and were subject to a global recall in 2021 due to the risks associated with the foam used in the products. The TGA alleges 11 models of Philips mechanical ventilators, continuous positive airway pressure (CPAP) machines and bi-level positive airway pressure (BiPAP) machines sold between June 2, 2019, and October 13, 2022, were unsafe, did not perform as intended and were therefore "unlawfully supplied". It estimates 44,000 devices were sold in that period. The devices contained a polyester-based polyurethane (PE-PUR) foam to reduce noise and vibration from the machine but Philips found the foam could degrade into particles that could be inhaled or ingested by the user. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences to patients," the TGA's statement of claim to the Federal Court states. The TGA alleges Philips was aware of the risks associated with the foam as early as 2015 but failed to take any action until 2021, when the devices were recalled. The TGA has submitted a range of documents it alleges demonstrate that Philips had prior knowledge of the defect, including a report from 2013 which refers to the death of a patient that year who used a particular ventilator called the Trilogy 100, which is named in the legal action. Following the global recall, Philips replaced the PE-PUR foam in the Trilogy 100 with silicone foam but by the following year it announced the new silicone foam could potentially separate from the plastic backing it was adhered to and block the air inlet. The statement of claim said this could lead to "ventilation failure or underventilation … [which] could in turn result in hypoventilation, hypoxemia, hypercapnia and asphyxia". The TGA alleges Philips did not conduct adequate risk analysis of the use of silicone foam with the adhesive. The TGA alleges exposure to the foam particles could cause short-term effects such as skin, eye and respiratory tract irritation, inflammatory responses, headaches, asthma, effects on the reproductive system and neoplasia (abnormal growth of tissue), while long-term exposure could be carcinogenic (potentially cause cancer). In a statement to the ABC, Philips Australia said since June 2021 it had conducted extensive testing with five independent, certified testing laboratories and third-party experts, and that, based on the test results, the experts concluded the devices were "not expected to result in appreciable harm to health in patients". "Philips will review the concise statement filed in the Federal Court by the Therapeutic Goods Administration and engage constructively in the required court processes," a spokesperson said. "Patient safety and quality is our number one priority, and we are focused on working closely with regulators to ensure we achieve the highest standards in the delivery of health care." The company noted the proceedings covered alleged activities in the lead-up to and during the 2021 recall but did not make allegations regarding the quality of Philips's current products. A class action against Philips lodged by consumers of the affected devices is also currently before the Federal Court in Victoria. The claim is being led by retired nurse Eva Lindbloom and aims to seek compensation for those who have suffered injury, loss or damage due to their use of the products. Last year Philips reached a $US1.1 billion ($1.7 billion) deal to settle legal action in the US over the devices. And a cross-border European class action is currently underway.
The Advertiser
4 days ago
- The Advertiser
Tech giant sued over sleep aid foam inhalation 'risk'
An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said. An alleged risk of patients breathing in or swallowing small particles of foam from degrading sleep aids has prompted the federal government to take legal action. Multinational health technology company Philips is accused of selling defective ventilators aimed at assisting with sleep apnoea and, after those products were recalled in June 2021, selling a further device which was also dangerous. In the lawsuit filed on Monday, the Therapeutic Goods Administration claims both sets of devices did not meet Australian safety standards. Devices sold prior to June 2021 contained a polyester-based polyurethane foam used for noise suppression. "There was a real risk of the (foam) degrading and then particulates being inhaled or ingested by the patient," the agency wrote in a statement. The potential harms from these devices included skin, eye and respiratory tract irritation, headaches, asthma and impacts on the reproductive system. Long-term exposure could damage or kill a patient's cells, cause genetic damage or cause cancer, the health watchdog alleges. "The probability of degradation, and consequential harm to the patient, was unacceptable, given the potentially serious consequences," the lawsuit claims. Philips did not conduct any risk analysis on the products until early 2021, the government agency says. Ten devices sold under the BiPAP, DreamStation, OmniLab and REMstar brands were recalled globally in June that year. After this date, Philips allegedly sold a further defective device, the Trilogy 100. This contained silicone foam which could become detached from its housing, obstructing the air path. Potential adverse health effects included increased carbon dioxide levels or low oxygen levels in the patient's blood. The TGA is seeking pecuniary penalties and orders that Philips pay its legal costs. A Philips spokeswoman said the lawsuit only revolved around the company's activities before and during the 2021 recall. "The proceeding does not make allegations about the quality and safety of products currently marketed in Australia by Philips," she said. The spokeswoman said extensive testing had been conducted internally as well as with five independent laboratories and third-party experts since June 2021. This testing concluded that the use of Philips sleep therapy devices presently sold on the market "is not expected to result in appreciable harm to health in patients". Philips would review the court documents filed by the TGA and engage constructively as required, she said.
